纳尔特雷与普拉佐辛增强用于酒精使用障碍:随机对照的概念验证试验结果
Tracy L Simpson1,2, Carol Achtmeyer1, Lisa Batten1
1Center of Excellence in Substance Addiction Treatment and Education (CESATE), Veterans Affairs (VA) Puget Sound Health Care System, 1660 So. Columbian Way, Seattle, WA 98108.
Alcohol and alcoholism (Oxford, Oxfordshire)
|September 13, 2024
概括
将普拉佐辛添加到纳尔特雷克松中显著改善了退伍军人的酒精使用障碍的结果. 与单独使用纳尔德相比,这种组合治疗显示出更大的渴望和大量饮酒日减少.
科学领域:
- 药理学 药理学是指药理学的学科.
- 精神病学是一个精神病学.
- 临床试验 临床试验
背景情况:
- 酒精使用障碍 (AUD) 是一种普遍存在的疾病,具有重大公共卫生影响.
- 纳尔特雷克松是一种类药物受体对抗剂,是AUD的常见药物治疗方法.
- 需要更有效的治疗方法来改善AUD的结果,特别是在老兵人群中.
研究的目的:
- 进行一项概念验证随机对照试验,评估纳尔特雷克松与普拉佐辛联合用于退伍军人AUD.
- 为了确定纳尔特雷克松和普拉佐辛的组合是否优于单独的纳尔特雷克松在减少酒精渴望和消费方面.
主要方法:
- 31名患有AUD的积极饮酒的退伍军人被随机分为四组:纳尔特雷克松加普拉佐辛,纳尔特雷克松加安慰剂,普拉佐辛加安慰剂或安慰剂加安慰剂.
- 该试验持续了6周,用普拉佐辛定位到目标剂量,每天服用纳尔特雷克松.
- 主要结局包括宾夕法尼亚州酒精渴望量表 (PACS),饮酒日数百分比 (PDD) 和重度饮酒日数百分比 (PHDD).
主要成果:
- 与基线相比,纳尔特雷加普拉佐辛组的PACS,PDD和PHDD减少了50%以上.
- 这些减少至少是纳尔特雷加安慰剂组观察到的两倍.
- 纳尔特雷克松加上普拉佐辛和纳尔特雷克松加上安慰剂组之间的标准化效应大小在所有主要结局中都超过0.8.
结论:
- 纳尔特雷克松的普拉佐辛增强显示出一个有希望的信号,用于提高治疗AUD的疗效.
- 这些发现支持一个更大的,最终的随机对照试验的合理性,以证实这些结果.
- 综合疗法需要进一步研究,作为潜在的酒精使用障碍治疗方法.
相关概念视频
CNS Depressants: Alcohol and Nicotine
181
Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
181
Drugs for Treatment of Diarrhea-Predominant IBS
153
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
153


